首页> 美国卫生研究院文献>Pharmaceuticals >Obesity Drug Update: The Lost Decade?
【2h】

Obesity Drug Update: The Lost Decade?

机译:肥胖药物更新:失落的十年?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The growing worldwide obesity epidemic and obesity-related disorders present a huge unmet medical need for safe and effective anti-obesity medications. The discovery of leptin in 1994 was rapidly succeeded by a wave of related discoveries leading to the elaboration of a hypothalamic melanocortinergic neuronal circuit regulated by leptin and other central and peripheral signaling molecules to control energy homeostasis. The identification of specific neuronal subtypes along with their unique connections and expression products generated a rich target menu for anti-obesity drug discovery programs. Over the course of the last decade, several new chemical entities aimed at these targets have reached various stages or successfully completed the drug discovery/regulatory process only to be dropped or taken off the market. There are now in fact fewer options for anti-obesity drug therapies in late 2010 than were available in 2000. The challenge to discover safe and effective anti-obesity drugs is alive and well.
机译:全球范围内日益增长的肥胖流行病和与肥胖相关的疾病为安全有效的抗肥胖药物带来了巨大的医疗需求。瘦素的发现在1994年迅速被一系列相关发现所成功,从而导致了下丘脑由瘦素及其他中枢和外周信号分子调节以控制能量稳态的下丘脑黑皮质素能神经回路的建立。特定神经元亚型的识别以及它们独特的连接和表达产物为抗肥胖药物发现计划提供了丰富的目标菜单。在过去的十年中,针对这些目标的几个新的化学实体已经达到各个阶段,或者成功地完成了药物发现/监管过程,只是被放弃或从市场上撤下。实际上,与2000年相比,2010年末抗肥胖药疗法的选择数量越来越少。发现安全有效的抗肥胖药的挑战仍然存在。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号